Get to know our clinical trials
Ensayo aleatorizado abierto sobre la eficacia y la seguridad del zanidatamab en combinación con el tratamiento habitual frente a solo tratamiento habitual para el cáncer de vías biliares avanzado positivo para HER2
THE SPONSOR IS CONDUCTING THIS STUDY TO DETERMINE WHETHER ZANIDATAMAB COMBINED WITH THE REFERENCE TREATMENT IS SAFE AND WORKS TO TREAT UNRESECTABLE OR METASTATIC LOCALLY ADVANCED HER2-POSITIVE HER2-POSITIVE CVB.
Technical Summary
- RANDOMIZED OPEN-LABEL TRIAL OF THE EFFICACY AND SAFETY OF ZANIDATAMAB IN COMBINATION WITH STANDARD THERAPY VS. STANDARD THERAPY ALONE FOR HER2-POSITIVE ADVANCED BILE DUCT CANCER.
- Code EudraCT: 2023-508219-21-00
- Protocol number: JZP598-302
- Promoter: Jazz Pharmaceuticals, Inc.
- Molecule/Drug: zanidatamab
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.